bioAffinity Technologies, Inc. - Common Stock (BIAF)
0.2610
-0.0894 (-25.51%)
NASDAQ · Last Trade: Sep 16th, 5:30 PM EDT
Detailed Quote
Previous Close
0.3504
Open
0.3047
Bid
0.2567
Ask
0.2590
Day's Range
0.2500 - 0.3081
52 Week Range
0.1639 - 2.259
Volume
13,731,246
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
10,638,947
Chart
About bioAffinity Technologies, Inc. - Common Stock (BIAF)
bioAffinity Technologies, Inc. is a biotechnology company focused on developing innovative diagnostic and therapeutic solutions for the early detection and treatment of cancer. The company leverages its proprietary technologies to create advanced cellular and molecular products aimed at improving patient outcomes, particularly in areas where traditional methods fall short. By harnessing the power of biological mechanisms, bioAffinity seeks to provide healthcare professionals with novel tools for identifying cancer at its earliest stages and tailoring personalized treatment plans for patients. Read More
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released another compelling case study in which its flagship product, CyPath® Lung, identified cancer in a patient with an incidental finding of ground-glass lung nodules.
U.S. Medicine, a leading publication for federal healthcare professionals, has featured bioAffinity Technologies’ CyPath® Lung in its pulmonary issue, highlighting the test’s potential to improve lung cancer detection while lowering costs for the Department of Veterans Affairs (VA).
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company advancing noninvasive diagnostics for the early detection of lung cancer and other diseases, today announced the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors.
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced the closing of its previously announced private placement transaction for the purchase and sale of 990 shares of the Company’s Series B Convertible Preferred Stock (the “Preferred Stock”) and warrants (the “Private Placement Warrants”) to purchase approximately 6.7 million shares of common stock (the “Private Placement”).
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended June 30, 2025.
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into securities purchase agreements with several institutional and accredited investors (the "Purchasers") for the purchase and sale of 990 shares of the Company’s Series B Convertible Preferred Stock (the “Preferred Stock”) and warrants (the “Private Placement Warrants”) to purchase approximately 6.7 million shares of common stock (the “Private Placement”).
